The pharmacokinetics of voriconazole show a nonlinear dose-exposure relationship caused by inhibition of its own CYP3A-dependent metabolism. Because the magnitude of autoinhibition also depends on voriconazole concentrations, infusion rate might modulate voriconazole exposure. The impact of four different infusion rates on voriconazole pharmacokinetics was investigated.
Introduction
The azole antimycotic voriconazole improves clinical outcome and reduces mortality in patients with invasive fungal infections. Analyses of the exposure-response relationship indicate that optimal target plasma trough concentrations range between 1.5 and 4.5 μg ml -1 [3] and therapeutic drug monitoring is recommended to maximize therapeutic success [4] . Therefore, detailed knowledge is necessary to determine the optimal dose administration schedule. Voriconazole clearance depends on the activities cytochrome P450 (CYP) isozymes 3A, 2C19, 2C9 and flavin monooxygenase 3 as identified in vitro. Up to 6% of voriconazole is eliminated by the kidneys. The main circulating metabolite is voriconazole N-oxide, while in urine the N-oxide as well as hydroxyvoriconazole, dihydroxy-voriconazole, 4-hydroxy-voriconazole and their glucuronidated phase II-metabolites are found [5, 6] . The bioavailability of therapeutic 400 mg voriconazole doses is high [7] . Therefore, switching the route of administration is possible without dose adaptation [8] .
Voriconazole's pharmacokinetics are nonlinear with dosedependent bioavailability and dose-dependent elimination half-life [9, 10] . The bioavailability of smaller doses is considerably lower, e.g. 39% for subtherapeutic 50 mg doses [9] . Voriconazole exposure increases 40-fold when increasing the oral dose 8-fold (from 50 to 400 mg) [9] , and 3.8-fold, when doubling a 200 mg dose [10] . This has been attributed to saturation of presystemic and systemic voriconazole metabolism at therapeutic doses [8] . In our recently published study we presented evidence for dose-dependent CYP-mediated autoinhibition as mechanism for dose nonlinearity [9] as it is the case for autoinhibitors such as telithromycin [11] . In vitro, voriconazole K i for competitive inhibition of CYP3A4-mediated midazolam metabolism is 0.66 μmol l -1 and 2.97 μmol l -1 for noncompetitive CYP3A4
inhibition [12] . Furthermore voriconazole is a potent competitive inhibitor of CYP2B6 (K i < 0.5 μmol l -1 ), CYP2C9
(K i = 2.79 μmol l -1 ), and CYP2C19 (K i = 5.1 μmol l -1 ) [12] .
Concentration giving 50% inhibition (IC 50 ) reported for of CYP2C9-mediated tolbutamide metabolism was 8.4 μmol l -1 , for inhibition of CYP2C19 mediated S-mephenytoin metabolism 8.7 μmol l -1 [13] . Others found a solely competitive inhibition type for CYP3A4 with a K i of 0.15 μmol l -1 , and CYP3A5 with a K i of 0.2 μmol l -1 [14] . A study building a semiphysiological model determined a K i of 0.34 μmol l -1 [15] . Voriconazole does not influence CYP1A2, 2E1 or 2D6 activity [16] CYP3A4, 2C9 and 2C19 dependent metabolism has been demonstrated in human liver microsomes (HLMs), among recombinant CYP isoforms CYP2C19 and CYP3A4 had voriconazole N-oxidation activities, but not CYP2C9. Apparent Michaelis constant (K M ) and maximum velocity (V max ) values of CYP2C19 and CYP3A4 for voriconazole N-oxidation were 14 μmol l -1 and 0.22 nmol min -1 nmol -1 CYP2C19 and 16 μmol l -1 and 0.05 nmol min -1 nmol -1 CYP3A4, respectively [17] .
In vivo, the extent of CYP3A inhibition depends on route of administration and dose. Coadministration of a 400-mg oral voriconazole dose increases the exposure of the CYP3A marker substrate midazolam given orally by 595% to 885% [9, 18] . When coadministered with 400 mg intravenous (IV) voriconazole, oral midazolam exposure increases only by 294% [9] . Similarly, an oral 50 mg voriconazole dose leads to an 84% increase of oral midazolam exposure while 50 mg IV has no effect [9] . Even when being a CYP3A inhibitor in itself, other strong inhibitors of CYP3A can further increase voriconazole exposure as demonstrated by the decrease in clearance following the administration of ritonavir [19] . Voriconazole clearance is also dependent on CYP2C19 as demonstrated by the 41% increase of AUC at steady-state when coadministering omeprazole [20] Because CYP2C19 is polymorphic, voriconazole clearance is CYP2C19 genotype dependent in vivo as shown in a 66% lower clearance in poor metabolizers (PMs; *2/*2 allele) compared to extensive metabolizers (EMs; *1/*1 allele) and a genotype-dependent bioavailability (95% in CYP2C19 EM, and 75% in PM) [21] . When CYP3A was inhibited in CYP2C19 PMs, clearance dropped from 158 AE 54 to 22 AE 11 ml min -1 [19] .
Because voriconazole systemic clearance (CL) and CYP3A inhibition are dose-dependent [10] , the question arises whether its exposure also depends on rate of infusion. We hypothesized that lower infusion rates would lead to less autoinhibition and hence supraproportionally lower peak plasma concentrations and / or exposure. If correct, then from a clinical point of view the highest possible and safe infusion rate should be chosen or in cases of low plasma concentrations, an increase of infusion duration could be attempted. From a mechanistic point of view concentration dependence of CYP-mediated autoinhibition is in line with a competitive inhibition mechanism. We therefore designed a trial to investigate the pharmacokinetics of voriconazole and its N-oxide metabolite in healthy volunteers after 400 mg doses administered IV over 2 h, 4 h and 6 h and compared it to 100 mg voriconazole administered over 4 h. 
Materials and methods

Study design
Participants were recruited into a fixed-sequence study comparing the IV pharmacokinetics of single therapeutic (400 mg) and subtherapeutic (100 mg) voriconazole doses with different infusion rates and concurrent changes in midazolam pharmacokinetics. Voriconazole administrations were separated by a wash-out phase of at least 7 days. Participants received 100 mg voriconazole IV over 4 h (A: 100 mg 4 h ; Figure 1 ). Oral microdosed midazolam as a CYP3A probe drug was administered at the end of each infusion.
Study medication
Voriconazole (Vfend; Pfizer Pharma GmbH, Berlin, Germany) for IV administration was prepared according to the manufacturer's instructions and dissolved in normal saline to yield a total volume of 50 ml.
We used oral microgram doses of midazolam, which do not exhibit pharmacological effects for CYP3A phenotyping [22, 23] . All midazolam doses were prepared from commercially available vials containing 5 mg midazolam in 5 ml (Dormicum V: Roche, Grenzach-Wyhlen, Germany). To prepare the oral solution, 3 μg of midazolam were diluted in 100 ml of water.
Blood and urine sampling
On days of voriconazole IV administration, blood and urine was sampled predose, and over a period of 48 h after start of infusion. In group A, blood samples were taken predose, and 
CYP2C19 genotyping
For genotyping, genomic DNA was isolated from white blood cells using the NucleoSpin Blood kit (Macherey-Nagel, Düren, Germany) according to the manufacturer's instructions. The presence of the alleles *2 and *3 was determined using the simple probe/hybridization probe format applied by the LightMix Kit CYP2C19*2*3 (TIBMolbiol, Berlin, Germany) on a LightCycler 480 (Roche Applied Science, Mannheim, Germany) according to the manufacturer's instructions. The presence of the alleles *4 and *17 was determined using the hybridization probe format on a LightCycler 480 according to a previously published method [24] .
Assay for inhibition of CYP2C19 and CYP3A4 by voriconazole-N-oxide
Inhibition of CYP2C19 and CYP3A4 was assessed with the P450-Glo CYP2C19 Screening System P450-Glo and the P450-Glo CYP3A4 Screening System (Promega Corporation, Madison, WI, USA) according to the manufacturer's instructions. The kits contain a luminogenic substrate (luciferin-H EGE for CYP2C19 and luciferin-IPA for CYP3A4), which is converted by the respective CYP into luciferin. When incubated with the luciferin detection reagent of the kit a light signal is generated which correlates to the activity of the respective enzyme. Voriconazole-N-oxide was tested for its ability to inhibit the production of the luminescent signal. Eight concentrations in triplicates ranging from 0.05 up to 100 μmol l -1 were tested and each experiment was conducted thrice. IC 50 values were calculated using a fourparameter fit using Prism version 6.07 (GraphPad Software, Inc., La Jolla, CA, USA).
Analytical assays
Voriconazole, midazolam and their metabolites were quantified as reported earlier [9, 25] . The lower limit of quantitation (LLOQ) was 0.6 ng ml -1 for voriconazole, and 3.0 ng ml -1 for voriconazole N-oxide in plasma. In urine LLOQ was 30 ng ml -1 for voriconazole and voriconazole N-oxide and 230 ng ml -1 for hydroxy-voriconazole and dihydroxyvoriconazole. The within-batch and batch-to-batch accuracies for voriconazole and voriconazole N-oxide in plasma and urine were always within 100 AE 15%, and the corresponding precisions were <15%, with the exception of voriconazole Noxide at the lowest urine quality control sample (29%). The LLOQ of midazolam and 1′-hydroxy-midazolam was 0.1 pg ml -1 and 0.28 pg ml -1 with corresponding 
CYP3A phenotyping
A validated limited sampling strategy based on plasma samples taken 2-4 h after midazolam dose was used to determine CYP3A activity [26] . To calculate estimated midazolam clearance, we constructed the AUC 2-4 using molar midazolam plasma concentrations at t = 2 h, 2.5 h, 3 h and 4 h with Prism 6.07. These were normalized to a midazolam dose of 1 mg and then eCLmet was calculated using the following formula: eCLmet =5668/ AUC 2-4 (h.nmol ml -1 )/mg midazolam [26] .
Pharmacokinetic analysis and statistical evaluation
All pharmacokinetic parameters of voriconazole and its metabolites were determined using Kinetica 5.0 (Thermo, Waltham, MA, USA). AUC 0-∞ was calculated with the loglinear model implemented in Kinetica 5.0 [27] . C max was the maximum concentration reached, T max was determined as time to reach maximum concentration. Half-life (t 1/2 ) was calculated as ln2/k. The apparent volume of distribution at steady state (V ss ) was calculated as (Dose*MRT)/(AUC 0-∞ ). Systemic clearance (CL sys ) was calculated as CL sys = dose/ AUC 0-∞ [27] . Metabolic ratio in plasma was calculated as molar AUC 0-24 (voriconazole N-oxide) / molar AUC 0-24 (voriconazole) while the metabolic ratio in urine was based on the amount excreted in 48 h urine (Ae): molar Ae (voriconazole N-oxide) / molar Ae Figure 2 Mean (AE standard deviation) plasma concentration-time profiles of voriconazole (main) and voriconazole N-oxide (insert) of 12 healthy volunteers who were administered a single intravenous dose of 100 mg of voriconazole over 4 h (black diamonds), 400 mg of voriconazole over 6 h (black triangles), 400 mg of voriconazole over 4 h (black circles), and 400 mg of voriconazole over 2 h (black squares) on four different occasions with a washout phase of ≥7 days between each dosing (voriconazole). When looking at bioequivalence, the geometric mean ratio and 90% confidence interval of AUC or C max between test and comparator were calculated. When the 90% confidence interval was within the margins of 80-125%, we considered both administration schedules to be bioequivalent.
The statistical analysis was conducted using Prism 6.07. We have run a nonparametric one-way ANOVA (Friedman test) corrected for multiple comparisons (Dunn's posthoc test).
Results
Voriconazole plasma kinetics
Plasma concentration-time profiles of voriconazole and its N-oxide metabolite are shown in Figure 2 and Figure S1 . The pharmacokinetic parameters of voriconazole following different administration schedules are reported in Table 1 . C max decreased with lower infusion rates. C max after a 4 h infusion, and after a 6 h infusion was 29% and 51% lower compared to a 400 mg 2 h -1 infusion and outside of the bioequivalence margins (0.80-1.25; Table 2 ). Dosedisproportionality of voriconazole was also observed for the 100 mg dose, were dose-normalised C max was 28% lower compared to the 400 mg 4 h -1 infusion (Table 2) .
Voriconazole exposure (AUC) was dose dependent and infusion rate dependent (Table 1) . AUC after a 400-mg dose decreased with longer infusion times. Administered over 4 h, and 6 h, the relative AUC was 89% (90% confidence interval: 81-98%; p = 0.051 vs. 2-h infusion), and 84% (80-88%; p < 0.0001 vs. 2-h infusion), respectively (Table 2) . Hence, the voriconazole exposure (AUC) of the 400 mg 6 h -1 administration schedule is 16% lower but still within bioequivalence margins (0.80-1.25) of the 400 mg 2 h -1 administration schedule (Table 2 ). Dose-normalised AUC was 34% lower following a 100 mg 4 h -1 -infusion compared to a 400 mg 4 h -1 infusion (Table 2) . Concurrently, the total systemic clearance (CL sys ) was uniformly lower after 400 mg compared to 100 mg. Also, CL sys was infusion rate-dependent ( Figure 3 ).
Voriconazole metabolites
In contrast to the parent compound, exposure (AUC) with voriconazole N-oxide after 400 mg IV voriconazole was Table 1 Voriconazole pharmacokinetics after intravenous (IV) administration of 100 mg voriconazole over 4 h and 400 mg voriconazole over 2, 4, and 6 h Effect of infusion rate on voriconazole kinetics independent of infusion rate (Table 1) . Corresponding to the changes of the parent drug, the plasma metabolic ratios were approximately 20% higher when voriconazole was infused over 4 h and 6 h compared to the 2 h infusion, but was independent of dose ( Table 2) . Doseadjusted AUC of voriconazole N-oxide was 44% lower after a 100 mg dose ( Table 2 , p < 0.0001). Interestingly, urinary recovery was about 10% lower following a 100 mg dose compared to the 400 mg doses (group A vs. D P = 0.0016; Table 3 ), which was mainly due to approximately 10% reduced urinary recovery of the N-oxide metabolite, but the recovery of the hydroxymetabolite and dihydroxy-metabolite was significantly reduced also (Table 3 ). The molar metabolic ratio in urine was significantly increased by 24% when the 400-mg dose was administered over 6 h compared to the 4 h and 2 h infusions (Table 3 ).
In vitro inhibition of CYP2C19 and CYP3A4 by voriconazole N-oxide
Mean IC 50 of voriconazole N-oxide was 146 AE 23 μmol l -1 for CYP3A4 and 40.2 AE 4.2 μmol l -1 for CYP2C19 ( Figure S2 ).
CYP3A phenotyping
Geometric mean (95% confidence interval) of eCLmet was 1070 ml min -1 (800-1420). eCLmet of all 12 participants was 516 ml min -1 (420-640) following the 100 mg 4 h for the 400 mg 2 h -1 infusion ( Figure 4) . As a comparator, we added recent (<1 year) values for estimated metabolic midazolam clearance (eCL met ) as a marker for CYP3A activity for the eight participants for whom they were available from baseline measurements of a prior trial participation ( Figure 4 ).
CYP2C19 genotype data
No CYP2C19 PMs (expressing two defective alleles *2, *3 or *4) were among the 12 analysed participants. Genotype data on an individual level are reported in Table S1 .
Safety
Only mild adverse events occurred during the trial. Two cases of CTCAE (Common Terminology Criteria for Adverse 
Discussion
In this clinical trial, we demonstrate that peak plasma concentration, exposure and volume of distribution of intravenous voriconazole are infusion rate-dependent. The most important change that occurred in quantitative terms was the strong decrease in C max when decreasing the infusion rate. The reduction of C max by 50% when administering voriconazole over 6 h is suggestive for a faster elimination rate from plasma during the infusion. From a clinical point of view this finding is quite significant as the fungicide effect is concentration dependent and patients infected with species with a high minimum inhibitory concentration will benefit from quickly achieving high plasma concentrations. The reduction of voriconazole exposure was less pronounced than changes in C max but statistically significant. The observed differences suggest that differences in administration regimens and thus exposure differences during the administration phase probably modified voriconazole clearance in a concentration-dependent manner. Still the AUC after 400 mg were bioequivalent independent of the duration of the infusion. A comparable effect of infusion rate on parent drug and metabolite pharmacokinetics has recently been reported for CYP1A2-dependent bendamustine biotransformation in rats, where longer infusion times correlated with lower AUC [28] . Interestingly, V ss increased 1.5-fold when comparing the 400 mg 6 h -1 group to the 400 mg 2 h -1 group, while no difference in terminal elimination half-life (t 1/2 ) was observed. The V ss of the 400 mg 2 h -1 group was equal to previously reported values after multiple 3 mg kg -1 IV doses while a V ss of 220 l has been reported after single 3 mg kg -1 IV doses [29] . In consequence, steady-state plasma concentration will be achieved faster in patients when choosing higher infusion rates and higher doses. The extent of AUC reduction in our trial was only small, still within the bioequivalence range, and hence is not deemed clinically significant. However, duration of infusion should only be increased with caution in clinical practice
Figure 3
Individual systemic clearance of voriconazole of 12 healthy volunteers who were administered a single intravenous dose of 100 mg of voriconazole over 4 h (A), 400 mg of voriconazole over 6 h (B), 400 mg of voriconazole over 4 h (C), and 400 mg of voriconazole over 2 h (D) on 4 different occasions with a washout phase of ≥7 days between each dosing. A Friedman's test followed by Dunn's multiple comparisons test was run, an adjusted P-value <0.05 was considered statistically significant Table 3 Geometric means [95% confidence interval] of amount excreted in urine and urinary recovery of voriconazole and metabolites of 12 healthy volunteers receiving 100 mg voriconazole over 4 h and 400 mg voriconazole over 2, 4, and 6 h Effect of infusion rate on voriconazole kinetics and prolonging the administration or even administration by continuous infusion will yield the lowest exposures and thus the most expensive treatment regimen. Concerning metabolite kinetics, no alteration of the N-oxide metabolite exposure was observed when varying infusion rates. With a~20% lower voriconazole AUC in the 400 mg 6 h -1 group, the relative metabolite formation rate was 20% higher. This is suggestive for accelerated voriconazole biotransformation at lower infusion rate, reflecting rapid and concentration-dependent hepatic autoinhibition of the metabolism. The trial was of an explorative nature using four different infusion rates, it was not powered to detect a difference of 20% of voriconazole-N-oxide formation. Overall, comparing the 100 mg 4 h -1 group with the 400 mg 4 h -1 group, a 4-fold increase in dose has the greater impact on pharmacokinetics than a reduction of infusion rate by 66%. While overall exposure with voriconazole N-oxide was 8-fold lower (Table 1) , plasma metabolic ratio did not differ between the 100 mg 4 h -1 schedule and the 400 mg 4 h -1 schedule (Table 1) . Interestingly though, urinary recovery of total dose was 10% lower with the 100 mg dose. This was mostly due to reduced N-oxide recovery. IV doses of 100 mg voriconazole also inhibited CYP3A activity, but to a lesser extent than the 400 mg doses. A possible explanation is that at lower doses, metabolism is shunted towards a more CYP3A dependent elimination pathways. N-oxide is both formed by CYP3A4 and CYP2C19, while formation of the 4-hydroxy-voriconazole metabolite is solely CYP3A4 dependent [5, 17] . Estimated midazolam metabolic clearance (eCL met ) was lower in the 400 mg 6 h -1 infusion group than in the 400 mg 2 h -1 infusion group (Figure 4 ). This finding seemed contradictory to the concept of increased CYP3A-and CYP2C19-mediated voriconazole biotransformation at lower infusion rates. Exposure with voriconazole N-oxide during the time interval from start of infusion until 2 h post end-of-infusion markedly differs between groups B, C and D (Figure 2 ) Considering the different time points of midazolam administration relative to the start of infusion, exposure over time with voriconazole N-oxide was different and highest when midazolam was administered 6 h after start of infusion. We therefore postulated that voriconazole metabolites might inhibit CYP isozymes similar to itraconazole metabolites [30] and subsequently analysed the perpetrator potential of voriconazole N-oxide. Peak voriconazole N-oxide plasma concentrations were approximately 11 μmol l -1 following the 400 mg IV single dose in our trial (Figure 2 ). The plasma protein binding of voriconazole is 58% and is not determined for its N-oxide metabolite [3] . Regarding the total and estimating the free plasma concentrations, N-oxide mediated CYP3A4-inhibition is unlikely (IC 50 = 146 μmol l [31] , the inhibitory effect will mostly come from the parent drug and to a much lesser extent for CYP2C19 from the N-oxide metabolite. eCL met was reduced by about 50% compared to baseline in the 100 mg 4 h -1 group, while we recently observed that 50 mg IV voriconazole does not alter oral midazolam clearance [9] .
Still with a 100 mg dose, midazolam clearance was 2-3 times higher than following a 400 mg dose (Figure 4 ).
Limitations
There are some limitations for the results of this trial. Only a single IV dose was investigated and the situation can be different when steady-state is reached, and both metabolite and parent levels are higher, thus exerting a stronger inhibition of the CYP3A system [9, 18, 26] . Concerning the midazolam drug interaction data, baseline values were not assessed during the study but recent values from other study participations were taken, when available (8 of 12). This might bias baseline as there is a slight seasonal variability in midazolam disposition [32] . No CYP2C19 PMs were included in this trial. Smaller absolute effects but higher relative effects because of lack of CYP2C19 activity are expected in this population. Also, there are differences in the timing of food administration and intake of the midazolam oral solution that may affect drug disposition.
Conclusion
In conclusion, we have demonstrated a minor effect of rate of infusion on voriconazole exposure for 400-mg doses. Lowering infusion rate by 67% leads to a 50% reduction in C max and 16% reduction of exposure. These and previous findings confirm that voriconazole pharmacokinetics are modulated by autoinhibition. We expand this information to duration of parenteral voriconazole administration, and suggest an inhibitory contribution of the voriconazole N-oxide metabolite to CYP2C19 dependent metabolism. In the light of the data presented here and from our previous work [9] , dose is more relevant than infusion rate. Findings concerning CYP3A4 inhibition are consistent. Only participants with functional CYP2C19 protein were enrolled, hence the mechanism of CYP autoinhibition also extends to CYP2C19 mediated voriconazole metabolism in EMs, as voriconazole and its metabolite both inhibit 2C19. In clinical practice, infusion rate should not deliberately be chosen or prolonged because this can trigger reduced exposure. Also, faster infusion rates could be explored, to reach higher plasma levels of voriconazole. While there is a positive association between C max and visual adverse events for single dose voriconazole [33] , oral doses were tested up to 1600 mg single dose for QT-study, leading to a C max of 10 000 ng ml -1 [34] . These concentrations still were safe and only had marginally more (70 vs. 60) treatmentrelated adverse events. Overall, voriconazole is well tolerated compared to other azole antimycotics and infusion reactions are rare [35] .
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Figure 4
Estimated metabolic midazolam clearance (CL met ) after administration of 100 mg of intravenous voriconazole over 4 h, or 400 mg over 2 h, 4 h or 6 h. p < 0.05 as determined by the Friedmann's test followed by Dunn's multiple comparisons test was seen as statistically significant. * Midazolam estimated metabolic clearance without comedication of eight participants from whom recent CYP3A data (< 1 year) was available from earlier trial participations [7] .
Figure S1 Log transformed mean (AE standard deviation) plasma concentration-time profiles of voriconazole (main) and voriconazole N-oxide (insert) of 12 healthy volunteers who were administered a single intravenous dose of 100 mg of voriconazole over 4 h (black diamonds), 400 mg of voriconazole over 6 h (black triangles), 400 mg of voriconazole over 4 h (black circles), and 400 mg of voriconazole over 2 h (black squares) on four different occasions with a washout phase of ≥7 days between each dosing Figure S2 Concentration-dependent effect of voriconazole-N-oxide on CYP3A4 and CYP2C19 activity measured by using the P450-Glo CYP1A2 Screening System and the P450-Glo CYP2C19 Screening System P450-Glo. Depicted is one experiment of three with each concentration tested in triplicate (mean AE standard deviation) Table S1 Participant characteristics Effect of infusion rate on voriconazole kinetics
